First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas
| Autor: | Patnaik, A. *, Appleman, L.J., Tolcher, A.W., Papadopoulos, K.P., Beeram, M., Rasco, D.W., Weiss, G.J., Sachdev, J.C., Chadha, M., Fulk, M., Ejadi, S., Mountz, J.M., Lotze, M.T., Toledo, F.G.S., Chu, E., Jeffers, M., Peña, C., Xia, C., Reif, S., Genvresse, I., Ramanathan, R.K. |
|---|---|
| Zdroj: | In Annals of Oncology October 2016 27(10):1928-1940 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|